Leap Therapeutics price target lowered to $2 from $3 at Mizuho

Mizuho analyst Mara Goldstein lowered the firm’s price target on Leap Therapeutics (LPTX) to $2 from $3 and keeps a Buy rating on the shares. BeiGene (BGNE) will not opt-in to DKN-01 in Asia, excluding Japan, though the company will continue to supply tislelizumab for the DisTinGuish Part C trial, the analyst tells investors in a research note. This is a disappointment in that it would have provided added validation, but the decision could have been commercial rather than clinical, says the firm.